Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Several Big Pharma companies unveiled price increases for some 250 drugs during the first month of the year, according to data from 3 Axis Advisors. Most notably, Pfizer is raising the price of its ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

How has the relationship between Big Pharma and biotech evolved? And where do CROs fit into the mix? Dearth of VC funding forcing difficult biotech decisions The realities of the global economy ...